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Ansofaxine Hydrochloride
Ansofaxine hydrochloride (LY03005; 
LPM570065) is a triple reuptake inhibitor 
that inhibits serotonin, dopamine and nor-
epinephrine reuptake. This novel triple reup-
take inhibitor is a carboxylic acid ester pro-
drug of  desvenlafaxine. It is currently under 
development by Luye Pharma Group for 
the treatment of  major depressive disorder 
- a frequent and heterogeneous disorder in-
duced by a complex pattern of  genetic, epi-
genetic, developmental, and environmental 
factors [1-3].
Pathophysiology of  depression has been 
researched for decades with the aim of  pro-
ducing adequate pharmacotherapy. Today’s 
conventional antidepressants, such as selec-
tive serotonin reuptake inhibitors (SSRI’s) 
and serotonin and norepinephrine reuptake 
inhibitors (SNRI’s) involve inhibiting sero-
tonin and noradrenaline uptake from the 
synapse. Those mechanisms of  action are 
congruent with the monoamine hypothesis 
of  depression [4]. The aforementioned mol-
ecules are known to be effective, but they 
typically have been plagued by anhedonia, 
sexual dysfunction and inability to improve 
cognitive impairment. The listed symptom-
atology could be reduced by enhancing the 
dopamine neurotransmission. Additionally, 
the onset of  therapeutic action is delayed by 
several weeks, which as well acts as a limita-
tion in therapeutic efficacy [5]. 
In a study by Zhang and associates, anso-
faxine was shown to penetrate the rat stria-
tum, then convert into desvenlafaxine and 
manifest elevated total exposure collated with 
the administration of  desvenlafaxine. Bet-
ter penetration could be explained by slight 
solubility in water and enhanced lipophilicity 
towards desvenlafaxine, which help desvenla-
faxine to overcome obstacles of  drug deliv-
ery in vivo. Acute and chronic administration 
of  oral suspension of  ansofaxine increases 
the serotonin, dopamine and norepinephrine 
concentration more than the relative admin-
istration of  desvenlafaxine. Desvenlafaxine 
has in vitro IC50 values of  53 nM and 538 
nM for inhibition of  serotonin and norepi-
nephrine reuptake, while ansofaxine has in 
vitro IC50 values of  723 nM, 763 nM, and 
491 nM for serotonin, norepinephrine, and 
dopamine reuptake inhibition. Ansofaxine 
demonstrated better antidepressant-like ac-
tivity in the forced swim test (used to measure 
the depression-like behaviour in rats) after 
88
Archives of Psychiatry Research 2021;57:87-90 Back to the Future of Psychopharmacology
acute and chronic administration compared 
with desvenlafaxine. Ansofaxine also attenu-
ated the harmful effects of  the excessive ac-
tivation of  inhibitory 5-HT1A autoreceptors 
induced by desvenlafaxine. Those effects are 
linked to the fact that it takes several weeks 
to produce the antidepressant effect for pa-
tients treated with a SSRI or SNRI. Namely, 
the acute elevation of  serotonin levels pro-
duced by SSRI and SNRI activates 5-HT1A 
autoreceptors and leads to restrained firing 
rates in serotonergic neurons. It is important 
to emphasize that, compared with desvenla-
faxine, ansofaxine also might contribute to 
the enhancing of  dopamine neurochemical 
activity which could lead to aforementioned 
reduction of  anhedonia, sexual dysfunction 
and cognitive impairment. Enhancing do-
paminergic neurotransmission could as well 
counter the repercussions on 5-HT1A autore-
ceptors. In all probability, the elevation of  ex-
tracellular dopamine levels could activate D2 
receptors which would then lead to indirect 
attenuation of  the excessive activation of  in-
hibitory 5-HT1A autoreceptors [3].
Luye Pharma Group commenced anso-
faxine hydrochloride extended release Phase 
I healthy volunteer study in Japan at the end 
of  2019 [1]. Apart from Japan, the Group is 
executing LY03005 Phase II clinical trial in 
China for Ansofaxine Hydrochloride extend-
ed release tablets [6]. As of  March 2020, the 
U.S. Food and Drug administration (FDA) 
has accepted the filing of  a New Drug Ap-
plication for LY03005 [7].
All in all, LY03005 is anticipated to aid 
the preservation of  patients’ sexual function, 
to manifest a better safety profile with more 
rapid onset and higher efficacy, consequently 
providing better options in treatment [8]. Re-
search so far indicates that this new molecule 
could be a promising candidate for depres-
sion treatment because of  its comprehensive 
targeting of  the monoamine system. 
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Figure 1. The chemical structure of  LPM570065.
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